Inhibitors of monoamine oxidase (MAO) have shown therapeutic values in a variety of neurodegenerative
diseases such as depression, Parkinson’s disease and Alzheimer’s disease. Heterocyclic
compounds exhibit a broad spectrum of biological activities and vital leading compounds for the development
of chemical drugs. Herein, we focus on the synthesis and screening of novel single heterocyclic
derivatives with MAO inhibitory activities during the past decade. This review covers recent
pharmacological advancements of single heterocyclic moiety along with structure- activity relationship
to provide better correlation among different structures and their receptor interactions.
The vascular impact of IP‐TP receptor interactions